CBPO:NSD-China Biologic Products Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 119.99

Change

0.00 (0.00)%

Market Cap

USD 4.63B

Volume

0.39M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


China Biologic Products Holdings, Inc (CBPO) Stock Analysis:
Based on the China Biologic Products Holdings, Inc stock forecasts from 0 analysts, the average analyst target price for China Biologic Products Holdings, Inc is not available over the next 12 months. China Biologic Products Holdings, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of China Biologic Products Holdings, Inc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, China Biologic Products Holdings, Inc’s stock price was USD 119.99. China Biologic Products Holdings, Inc’s stock price has changed by +0.00 % over the past week, +0.00 % over the past month and +1.17 % over the last year.

About

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood l ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CBPO

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.59% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.59% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 1.17% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.17% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 1.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.33% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.28% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.28% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.54% N/A N/A N/A N/A
Risk Adjusted Return 29.17% N/A N/A N/A N/A
Market Capitalization 4.63B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.41 N/A N/A N/A N/A
Price/Book Ratio 2.35 N/A N/A N/A N/A
Price / Cash Flow Ratio 17.91 N/A N/A N/A N/A
EV/EBITDA 14.33 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 9.25% N/A N/A N/A N/A
Return on Invested Capital 8.68% N/A N/A N/A N/A
Return on Assets 5.82% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.23 N/A N/A N/A N/A
Short Percent 3.45% N/A N/A N/A N/A
Beta 0.42 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike